[Still strong reason for enthusiasm for a new stroke-preventing drug].
Oldgren
Jonas
J
Uppsala kliniska forskningscentrum (UCR), Akademiska sjukhuset och Uppsala universitet. Jonas.Oldgren@ucr.uu.se
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000069604:Dabigatran; D019317:Evidence-Based Medicine; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome
D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran